## Attv. Dkt. No. PW 27

tty. Dkt. No.	PW 277862
	(M#)

Invention: NUCLEOTIDE SEQUENCES ENCODING THE dapC GENE AND PROCESS FOR THE

**APPLICATION UNDER UNITED STATES PATENT LAWS** 

PRODUCTION OF L-LYSINE

Inventor (s): Bettina MÖCKEL

Anke WEISSENBORN Walter PFEFFERLE Michael HARTMANN Jörn KALINOWSKI Alfred PÜHLER

> Pillsbury Winthrop LLP Intellectual Property Group 1100 New York Avenue, NW Ninth Floor

Washington, DC 20005-3918

Attorneys

Telephone: (202) 861-3000

## This is a:

_		
	Provisional	Application
	i i ovisionai	ADDIICATOR

#### Regular Utility Application

#### Continuing Application

The contents of the parent are incorporated by reference

PCT National Phase Application

Design Application

Reissue Application

☐ Plant Application

Substitute Specification

Sub. Spec Filed

in App. No. \_\_\_/

Marked up Specification re

Sub. Spec. filed

In App. No /

## **SPECIFICATION**

The transform that the first first the first that t

# Nucleotide Sequences Encoding the dapC Gene and Process for the Production of L-Lysine

This application claims priority from German Application
No. 100 14 546.9, filed on March 23, 2000, the subject
matter of which is hereby incorporated herein by reference.

### BACKGROUND OF THE INVENTION

1 Field of the Invention

The invention provides nucleotide sequences encoding the
10 dapC gene and a process for the fermentative production of
L-lysine, using coryneform bacteria in which the dapC gene
(N-succinylaminoketopimelate transaminase gene) is
enhanced, in particular over-expressed.

- 2. Background Information
- 15 Amino acids, in particular L-lysine, are used in human medicine and in the pharmaceuticals industry, but in particular in animal nutrition.

It is known that amino acids are produced by fermentation of strains of coryneform bacteria, in particular

- 20 Corynebacterium glutamicum. Due to their great significance, efforts are constantly being made to improve the production process. Improvements to the process may relate to measures concerning fermentation technology, for example stirring and oxygen supply, or to the composition
- of the nutrient media, such as for example sugar concentration during fermentation, or to working up of the product by, for example, ion exchange chromatography, or to the intrinsic performance characteristics of the microorganism itself.
- The performance characteristics of these microorganisms are improved using methods of mutagenesis, selection and mutant selection. In this manner, strains are obtained which are resistant to antimetabolites, such as for example the lysine analogue S-(2-aminoethyl)cysteine, or are

auxotrophic for regulatorily significant metabolites and produce L-amino acids, such as for example L-lysine.

For some years, methods of recombinant DNA technology have likewise been used to improve strains of Corynebacterium which produce amino acids by amplifying individual amino acid biosynthesis genes and investigating the effect on amino acid production. Review articles on this subject may be found inter alia in Kinoshita ("Glutamic Acid Bacteria", in: Biology of Industrial Microorganisms, Demain and

10 Solomon (Eds.), Benjamin Cummings, London, UK, 1985, 115142), Hilliger (BioTec 2, 40-44 (1991)), Eggeling (Amino
Acids 6:261-272 (1994)), Jetten and Sinskey (Critical
Reviews in Biotechnology 15, 73-103 (1995)) and Sahm et al.
(Annuals of the New York Academy of Science 782, 25-39
15 (1996)).

#### SUMMARY OF THE INVENTION

It is an object of the invention to provide novel methods for the improved fermentative production of L-lysine.

Description of the Invention

20 L-lysine is used in human medicine, in the pharmaceuticals industry and in particular in animal nutrition. There is accordingly general interest in providing novel improved processes for the production of L-lysine.

Any subsequent mention of L-lysine or lysine should be 25 taken to mean not only the base, but also salts, such as for example lysine monohydrochloride or lysine sulfate.

The invention provides an isolated polynucleotide from coryneform bacteria containing at least one polynucleotide sequence selected from the group

30 a) polynucleotide which is at least 70% identical to a polynucleotide which encodes a polypeptide containing the amino acid sequence of SEQ ID no. 2,

- b) polynucleotide which encodes a polypeptide which contains an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID no. 2,
- c) polynucleotide which is complementary to the polynucleotides of a) or b), or
  - d) polynucleotide containing at least 15 successive nucleotides of the polynucleotide sequences of a), b) or c).

The invention also provides the polynucleotide according to 10 claim 1, wherein it preferably comprises replicable DNA containing:

- (i) the nucleotide sequence shown in SEQ ID no. 1, or
- (ii) at least one sequence which matches the sequence(i) within the degeneration range of the genetic code, or
- (iii) at least one sequence which hybridizes with the complementary sequence to sequence (i) or (ii) and optionally
- (iv) functionally neutral sense mutations in (i).
- 20 The invention also provides
  - a polynucleotide according to claim 4, containing the nucleotide sequence as shown in SEQ ID no. 1,
  - a polynucleotide which encodes a polypeptide which contains the amino acid sequence as shown in SEQ ID no. 2,
- 25 a vector containing the polynucleotide according to claim 1, in particular a shuttle vector or the plasmid vector pXT-dapCexp, which is shown in Figure 2 and is deposited under number DSM 13254 in DSM 5715.
- and coryneform bacteria acting as host cell which contain the vector.

The invention also provides polynucleotides which substantially consist of a polynucleotide sequence, which are obtainable by screening by means of hybridization of a suitable gene library, which contains the complete gene having the polynucleotide sequence according to SEQ ID no. 1, with a probe which contains the sequence of the stated polynucleotide according to SEQ ID no. 1, or a fragment thereof, and isolation of the stated DNA sequence.

Polynucleotide sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA in order to isolate full length cDNA which encode N-succinylaminoketopimelate transaminase and to isolate such cDNA or genes, the sequence of which exhibits a high level of similarity with that of the N-succinylaminoketopimelate transaminase gene.

Polynucleotide sequences according to the invention are furthermore suitable as primers for the production of DNA of genes which encode N-succinylaminoketopimelate transaminase by the polymerase chain reaction (PCR).

- Such oligonucleotides acting as probes or primers contain at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides.

  Oligonucleotides having a length of at least 40 or 50 nucleotides are also suitable.
- 25 "Isolated" means separated from its natural environment.
  - "Polynucleotide" generally relates to polyribonucleotides and polydeoxyribonucleotides, wherein the RNA or DNA may be unmodified or modified.
- "Polypeptides" are taken to mean peptides or proteins which 30 contain two or more amino acids connected by peptide bonds.

The polypeptides according to the invention include a polypeptide according to SEQ ID no. 2, in particular those having the biological activity of N-succinylaminoketopimelate transaminase and also those which are at least

70%, preferably at least 80%, identical to the polypeptide according to SEQ ID no. 2 and in particular are at least 90% to 95% identical to the polypeptide according to SEQ ID no. 2 and exhibit the stated activity.

5 The invention furthermore relates to a process for the fermentative production of amino acids, in particular L-lysine, using coryneform bacteria, which in particular already produce an amino acid and in which the nucleotide sequences which encode the dapC gene are enhanced, in particular over-expressed.

In this connection, the term "enhancement" describes the increase in the intracellular activity of one or more enzymes in a microorganism, which enzymes are encoded by the corresponding DNA, for example by increasing the copy number of the gene or genes, by using a strong promoter or a gene or allele which encodes a corresponding enzyme having elevated activity and optionally by combining these measures.

The microorganisms, provided by the present invention, may produce L-amino acids, in particular L-lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. The microorganisms may comprise representatives of the coryneform bacteria in particular of the genus

25 Corynebacterium. Within the genus Corynebacterium, the

species Corynebacterium glutamicum may in particular be mentioned, which is known in specialist circles for its ability to produce L-amino acids.

Suitable strains of the genus Corynebacterium, in 30 particular of the species Corynebacterium glutamicum, are for example the known wild type strains

> Corynebacterium glutamicum ATCC13032 Corynebacterium acetoglutamicum ATCC15806 Corynebacterium acetoacidophilum ATCC13870 Corynebacterium thermoaminogenes FERM BP-1539

Corynebacterium melassecola ATCC17965
Brevibacterium flavum ATCC14067
Brevibacterium lactofermentum ATCC13869 and
Brevibacterium divaricatum ATCC14020

5 and L-lysine producing mutants or strains produced therefrom, such as for example

Corynebacterium glutamicum FERM-P 1709
Brevibacterium flavum FERM-P 1708
Brevibacterium lactofermentum FERM-P 1712
Corynebacterium glutamicum FERM-P 6463
Corynebacterium glutamicum FERM-P 6464
Corynebacterium glutamicum DSM5715
Corynebacterium glutamicum DSM12866 and
Corynebacterium glutamicum DM58-1.

15 The inventors succeeded in isolating the novel dapC gene, which encodes the enzyme N-succinylaminoketopimelate transaminase (EC 2.6.1.17), from C. glutamicum.

The dapC gene, and also other genes from C. glutamicum, are isolated by initially constructing a gene library of this
20 microorganism in E. coli. The construction of gene libraries is described in generally known textbooks and manuals. Examples which may be mentioned are the textbook by Winnacker, Gene und Klone, Eine Einführung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990) or

- 25 the manual by Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989). One very well known gene library is that of E. coli K-12 strain W3110, which was constructed by Kohara et al. (Cell 50, 495-508 (1987)) in λ-vectors. Bathe et al.
- 30 (Molecular and General Genetics, 252:255-265, 1996)
  describe a gene library of C. glutamicum ATCC13032, which
  was constructed using the cosmid vector SuperCos I (Wahl et
  al., 1987, Proceedings of the National Academy of Sciences
  USA, 84:2160-2164) in E. coli K-12 strain NM554 (Raleigh et
- 35 al., 1988, Nucleic Acids Research 16:1563-1575). Börmann et al. (Molecular Microbiology 6(3), 317-326, 1992)) also

describe a gene library of C. glutamicum ATCC 13032, using cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980)). A gene library of C. glutamicum in E. coli may also be produced using plasmids such as pBR322 (Bolivar, Life

- 5 Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are in particular those E. coli strains with restriction and recombination defects. One example of such a strain is the strain DH5 $\alpha$ mcr, which has been described by Grant et al. (Proceedings of the
- 10 National Academy of Sciences USA, 87 (1990) 4645-4649). The long DNA fragments cloned with the assistance of cosmids may then in turn be sub-cloned in usual vectors suitable for sequencing and then be sequenced, as described, for example, in Sanger et al. (Proceedings of the National

  15 Academy of Sciences of the United States of America,
- 15 Academy of Sciences of the United States of America, 74:5463-5467, 1977).

The novel DNA sequence from C. glutamicum which encodes the dapC gene and, as SEQ ID no. 1, is provided by the present invention, was obtained in this manner. The amino acid sequence of the corresponding protein was furthermore deduced from the above DNA sequence using the methods described above. SEQ ID no. 2 shows the resultant amino acid sequence of the product of the dapC gene.

Coding DNA sequences arising from SEQ ID no. 1 due to the
degeneracy of the genetic code are also provided by the
invention. DNA sequences which hybridize with SEQ ID no. 1
or parts of SEQ ID no. 1 are also provided by the
invention. Conservative substitutions of amino acids in
proteins, for example the substitution of glycine for
alanine or of aspartic acid for glutamic acid, are known in
specialist circles as "sense mutations", which result in no
fundamental change in activity of the protein, i.e. they
are functionally neutral. It is furthermore known that
changes to the N and/or C terminus of a protein do not
substantially impair or may even stabilize the function
thereof. The person skilled in the art will find
information in this connection inter alia in Ben-Bassat et

al. (Journal of Bacteriology 169:751-757 (1987)), in O'Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences arising in a corresponding manner from SEQ ID no. 2 are also provided by the invention.

Similarly, DNA sequences which hybridize with SEQ ID no. 1 or portions of SEQ ID no. 1 are also provided by the

- invention. Finally, DNA sequences produced by the polymerase chain reaction (PCR) using primers obtained from SEQ ID no. 1 are also provided by the invention. Such oligonucleotides typically have a length of at least 15 nucleotides.
- 15 The person skilled in the art may find instructions for identifying DNA sequences by means of hybridization inter alia in the manual "The DIG System Users Guide for Filter Hybridization" from Roche Diagnostics GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal
- of Systematic Bacteriology (1991) 41: 255-260). The person skilled in the art may find instructions for amplifying DNA sequences using the polymerase chain reaction (PCR) inter alia in the manual by Gait, Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in
- 25 Newton & Graham, PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

It has been found that coryneform bacteria produce L-lysine in an improved manner once the dapC gene has been over-expressed.

- Over-expression may be achieved by increasing the copy number of the corresponding genes or by mutating the promoter and regulation region or the ribosome-binding site located upstream from the structural gene. Expression cassettes incorporated upstream from the structural gene
- 35 act in the same manner. It is additionally possible to increase expression during fermentative L-lysine production

by means of inducible promoters. Expression is also improved by measures to extend the lifetime of the mRNA. Enzyme activity is moreover enhanced by preventing degradation of the enzyme protein. The genes or gene constructs may either be present in plasmids in a variable copy number or be integrated in the chromosome and amplified. Alternatively, over-expression of the genes concerned may also be achieved by modifying the composition of the media and culture conditions.

- The person skilled in the art will find guidance in this connection inter alia in Martin et al. (Bio/Technology 3, 137-146 (1987)), in Guerrero et al. (Gene 138, 35-41 (1994)), Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (1988)), in Eikmanns et al. (Gene 102, 93-98 (1991)), in EP 0 472 869, in US 4,601,893, in Schwarzer and Pühler (Bio/Technology 9, 84-87 (1991), in Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in WO 96/15246, in Malumbres et al.
- 20 (Gene 134, 15-24 (1993)), in JP-A-10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)), in Makrides (Microbiological Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.
- 25 By way of example, the dapC gene according to the invention was over-expressed with the assistance of plasmids.
  - Suitable plasmids are those which are replicated in coryneform bacteria. Numerous known plasmid vectors, such as for example pZ1 (Menkel et al., Applied and
- 30 Environmental Microbiology (1989) 64: 549-554), pEKEx1 (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-1 (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBL1 or pGA1. Other plasmid vectors, such as for example those based on pCG4 (US-A 4,489,160), or
- 35 pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66,

119-124 (1990)), or pAG1 (US-A 5,158,891) may be used in the same manner.

One example of a plasmid by means of which the dapC gene may be over-expressed is the E. coli-C. glutamicum shuttle vector pXT-dapCexp. The vector contains the replication region rep of plasmid pGA1, including the replication effector per (US-A- 5,175,108; Nesvera et al., Journal of Bacteriology 179, 1525-1532 (1997)), the tetA(Z) gene, which imparts tetracycline resistance, of plasmid pAG1 (US-10 A- 5,158,891; GenBank entry at the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) with

Biotechnology Information (NCBI, Bethesda, MD, USA) with the accession number AF121000), together with the replication origin, the trc promoter, the termination regions T1 and T2 and the lacI<sup>q</sup> gene (repressor of the lac operon of E. coli) of plasmid pTRC99A (Amann et al. (1988), Gene 69: 301-315).

The shuttle vector pXT-dapCexp is shown in Figure 2.

Further suitable plasmid vectors are those with the assistance of which gene amplification may be performed by 20 integration into the chromosome, as has for example been described by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for the duplication or amplification of the hom-thrB operon. In this method, the complete gene is cloned into a plasmid vector which can 25 replicate in a host (typically E. coli), but not in C. glutamicum. Vectors which may be considered are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pGEM-T (Promega corporation, Madison, WI, USA), 30 pCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; US-A 5,487,993), pCR®Blunt (Invitrogen, Groningen, Netherlands; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)) or pEM1 (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516). The 35 plasmid vector which contains the gene to be amplified is

then transferred into the desired strain of C. glutamicum

by conjugation or transformation. The conjugation method is described, for example, in Schäfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)).

Transformation methods are described, for example, in

Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of "crossing over", the resultant strain contains at least two copies of the gene in question.

It has furthermore been found that, by replacing the amino acid L-proline in position 209 of the enzyme protein (c.f. SEQ ID no. 2) with another proteinogenic amino acid, in particular L-leucine (c.f. SEQ ID no. 4), with the exception of L-proline, enhancement occurs and coryneform bacteria bearing the corresponding amino acid replacement produce L-lysine in an improved manner. The replacement of L-proline with L-leucine in position 209 may preferably be achieved by replacing the nucleobase cytosine in position 716 with thymine as shown in SEQ ID no. 3.

Mutagenesis may be performed by conventional mutagenesis methods using mutagens such as for example N-methyl-N'-nitro-N-nitrosoguanidine or ultraviolet light. Mutagenesis may also be performed by using in vitro methods such as for example treatment with hydroxylamine (Molecular and General Genetics 145, 101 pp (1978)) or mutagenic oligonucleotides (T.A. Brown: Gentechnologie für Einsteiger, Spektrum Akademischer Verlag, Heidelberg, 1993) or the polymerase chain reaction (PCR), as is described in the manual by Newton and Graham (PCR, Spektrum Akademischer Verlag, Heidelberg, 1994).

The invention accordingly also provides DNA originating from coryneform bacteria which encodes

35 N-succinylaminoketopimelate transaminase, in which the amino acid sequence shown in SEQ ID no. 2 in position 209

is replaced with another amino acid, with the exception of L-proline. The invention also relates to coryneform bacteria which contain DNA in which the amino acid L-proline in position 209 of the enzyme protein (c.f. SEQ ID no. 2) is replaced with L-leucine (c.f. SEQ ID no. 4).

The invention furthermore provides coryneform bacteria which contain DNA in which the replacement of L-proline with L-leucine in position 209 proceeds by the replacement of the nucleobase cytosine in position 716 with thymine, as 10 shown in SEQ ID no. 3.

It may additionally be advantageous for the production of L-lysine to amplify or over-express not only the dapC gene, but also one or more enzymes of the particular biosynthetic pathway, of glycolysis, of anaplerotic metabolism, or of amino acid export.

For the production of L-lysine, for example, it is thus possible in addition to the dapC gene simultaneously to enhance, in particular over-express or amplify, one or more genes selected from the group

- the lysC gene, which encodes a feed-back resistant aspartate kinase (Kalinowski et al. (1990), Molecular and General Genetics 224, 317-324),
- the asd gene, which encodes aspartate semialdehyde dehydrogenase (EP-A 0 219 027; Kalinowski et al.(1991),
   Molecular Microbiology 5:1197-1204, and Kalinowski et al.(1991), Molecular and General Genetics 224: 317-324),
  - the dapA gene, which encodes dihydropicolinate synthase (EP-B 0 197 335),
- the dapB gene, which encodes dihydrodipicolinate
   reductase (GenBank entry accession number X67737;
   Pisabarro et al. (1993), Journal of Bacteriology, 175(9):
   2743-2749),

- the dapD gene, which encodes tetrahydrodipicolinate succinylase (GenBank entry accession number AJ004934; Wehrmann et al. (1998), Journal of Bacteriology 180: 3159-3163),
- the dapE gene, which encodes N-succinyldiaminopimelate desuccinylase (GenBank entry accession number X81379; Wehrmann et al. (1994), Microbiology 140: 3349-3356),
  - the dapF gene, which encodes diaminopimelate epimerase (DE: 199 43 587.1, DSM12968),
- the lysA gene, which encodes diaminopimelate decarboxylase (GenBank entry accession number X07563; Yeh et al. (1988), Molecular and General Genetics 212: 112-119),
- the ddh gene, which encodes diaminopimelate dehydrogenase 15 (Ishino et al. (1988), Agricultural and Biological Chemistry 52(11): 2903-2909),
  - the lysE gene, which encodes lysine export (DE-A-195 48 222),
- the pyc gene, which encodes pyruvate carboxylase

  (Eikmanns (1992), Journal of Bacteriology 174: 60766086),
  - the mgo gene, which encodes malate:quinone oxidoreductase (Molenaar et al. (1998), European Journal of Biochemistry 254: 395-403),
- 25 the zwal gene (DE: 19959328.0, DSM 13115),
  - the gdh gene, which encodes glutamate dehydrogenase (Börmann et al. (1992), Molecular Microbiology 6, 317-326).

It is preferred simultaneously to enhance one or more genes 30 selected from the group dapD, dapE and dapF.

It may furthermore be advantageous for the production of Llysine, in addition to enhancing the dapC gene, optionally in combination with one or more genes selected from the group dapD, dapE and dapF, simultaneously to attenuate

- 5 the pck gene, which encodes phosphoenolpyruvate carboxykinase (DE 199 50 409.1, DSM 13047) or
  - the pgi gene, which encodes glucose 6-phosphate isomerase (US 09/396,478, DSM 12969), or
- the poxB gene, which encodes pyruvate oxidase (DE: 19951975.7, DSM 13114), or
  - the zwa2 gene (DE: 19959327.2, DSM 13113), or
  - the sucC or sucD genes which encode succinyl CoA synthetase (DE: 19956686.0).

It may furthermore be advantageous for the production of Llysine, in addition to enhancing the dapC gene, optionally
in combination with one or more genes selected from the
group dapD, dapE and dapF, to suppress unwanted secondary
reactions (Nakayama: "Breeding of Amino Acid Producing
Micro-organisms", in: Over-production of Microbial

20 Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

For the purposes of L-lysine production, the microorganisms produced according to the invention may be cultured continuously or discontinuously using the batch process or the fed batch process or repeated fed batch process. A summary of known culture methods is given in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/ Wiesbaden, 1994)).

The culture medium to be used must adequately satisfy the requirements of the particular strains. Culture media for

culturing.

various microorganisms are described in "Manual of Methods for General Bacteriology" from the American Society for Bacteriology (Washington D.C., USA, 1981).

Carbon sources which may be used are sugars and

5 carbohydrates, such as glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose for example, oils and fats, such as soya oil, sunflower oil, peanut oil and coconut oil for example, fatty acids, such as palmitic acid, stearic acid and linoleic acid for example, alcohols, such as glycerol and ethanol for example, and organic acids, such as acetic acid for example. These substances may be used individually or as a mixture.

Nitrogen sources which may be used comprise organic compounds containing nitrogen, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources may be used individually or as a mixture.

Phosphorus sources which may be used are phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding salts containing sodium. The culture medium has additionally to contain salts of metals, such as magnesium sulfate or iron sulfate for example,

which are necessary for growth. Finally, essential growthpromoting substances such as amino acids and vitamins may
also be used in addition to the above-stated substances.
Suitable precursors may furthermore be added to the culture
medium. The stated feed substances may be added to the
culture as a single batch or be fed appropriately during

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used appropriately to control the pH of the culture. Foaming may be controlled by using antifoaming agents such as fatty

acid polyglycol esters for example. Plasmid stability may be maintained by the addition to the medium of suitable selectively acting substances, for example antibiotics. Oxygen or oxygen-containing gas mixtures, such as air for example, are introduced into the culture in order to maintain aerobic conditions. The temperature of the culture is normally from 20°C to 45°C and preferably from 25°C to 40°C. The culture is continued until the maximum quantity of lysine has formed. This aim is normally achieved within 10 to 160 hours.

Analysis of L-lysine may be performed by anion exchange chromatography with subsequent ninhydrin derivation, as described in Spackman et al. (Analytical Chemistry, 30, (1958), 1190).

- 15 The following microorganism has been deposited with Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty:
- Corynebacterium glutamicum strain DSM5715/pXT-dapCexp as DSM 13254.

The process according to the invention serves in the fermentative production of L-lysine.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Map of plasmid pEC-XT99A

25 Figure 2: Map of plasmid pXT-dapCexp

The abbreviations and names are defined as follows.

per: Gene for controlling copy number from pGA1 oriE: Plasmid-coded replication origin of E. coli rep: Plasmid-coded replication origin from C.

glutamicum plasmid pGA1

Ptrc: trc promoter from pTRC99A

T1, T2: Terminator regions 1 and 2 from pTRC99A

lacIq: Repressor gene of the Lac operon

25

Tet: Resistance gene for tetracycline

dapC: dapC gene from C. glutamicum

EcoRI: Restriction site of the restriction enzyme

EcoRI

5 EcoRV: Restriction site of the restriction enzyme

EcoRV

HindIII: Restriction site of the restriction enzyme

HindIII

KpnI: Restriction site of the restriction enzyme

10 KpnI

SalI: Restriction site of the restriction enzyme

SalI

SmaI: Restriction site of the restriction enzyme

SmaI

15 NdeI: Restriction site of the restriction enzyme

NdeI

BamHI: Restriction site of the restriction enzyme

BamHI

Ncol: Restriction site of the restriction enzyme

Ncol

XbaI: Restriction site of the restriction enzyme

XbaI

SacI: Restriction site of the restriction enzyme

SacI

DETAILED DESCRIPTION OF THE INVENTION

The present invention is illustrated in greater detail by the following practical examples.

#### Example 1

30 Production of a genomic cosmid gene library from Corynebacterium glutamicum ATCC 13032

Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described in Tauch et al., (1995, Plasmid 33:168-179) and partially cleaved with the restriction

35 enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, code no. 27-0913-02). The DNA

fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, code no. 1758250). The DNA of cosmid vector SuperCos1 (Wahl et al. (1987) Proceedings of the National Academy of Sciences USA 84:2160-2164), purchased from Stratagene (La Jolla, USA, product description SuperCos1 Cosmid Vector Kit, code no. 251301) was cleaved with the restriction enzyme XbaI (Amersham Pharmacia, Freiburg, Germany, product description XbaI, code no. 27-0948-02) and also dephosphorylated with shrimp alkaline phosphatase. The cosmid DNA was then cleaved with

ocde no. 27-0948-02) and also dephosphorylated with shrimp alkaline phosphatase. The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, code no. 27-0868-04). Cosmid DNA treated in this manner was mixed with the

15 treated ATCC 13032 DNA and the batch was treated with T4
DNA ligase (Amersham Pharmacia, Freiburg, Germany, product
description T4 DNA Ligase, code no. 27-0870-04). The
ligation mixture was then packed in phages using Gigapack
II XL Packing Extracts (Stratagene, La Jolla, USA, product

description Gigapack II XL Packing Extract, code no. 200217). E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) was infected by suspending the cells in 10 mM MgSO<sub>4</sub> and mixing them with an aliquot of the phage suspension. The cosmid library was infected and

25 titred as described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/l of ampicillin. After overnight incubation at 37°C, individual recombinant clones were 30 selected.

#### Example 2

Isolation and sequencing of the dapC gene

Cosmid DNA from an individual colony was isolated in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (product no. 27106, Qiagen, Hilden, Germany) and partially cleaved with the restriction

enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, product no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany,

- 5 product description SAP, product no. 1758250). Once separated by gel electrophoresis, the cosmid fragments of a size of 1500 to 2000 bp were isolated using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany). The DNA of the sequencing vector pZero-1
- 10 purchased from Invitrogen (Groningen, Netherlands, product description Zero Background Cloning Kit, product no. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, product no. 27-0868-04). Ligation of the cosmid fragments
- into the sequencing vector pZero-1 was performed as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then
- electroporated into the E. coli strain DH5αMCR (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) and plated out onto LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l of Zeocin. Plasmids of
- the recombinant clones were prepared using the Biorobot 9600 (product no. 900200, Qiagen, Hilden, Germany).

  Sequencing was performed using the dideoxy chain termination method according to Sanger et al. (1977, Proceedings of the National Academies of Sciences U.S.A.,
- 74:5463-5467) as modified by Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (product no. 403044, Weiterstadt, Germany) was used. Separation by gel electrophoresis and analysis of the
- sequencing reaction was performed in a "Rotiphorese NF" acrylamide/bisacrylamide gel (29:1) (product no. Al24.1, Roth, Karlsruhe, Germany) using the "ABI Prism 377"

sequencer from PE Applied Biosystems (Weiterstadt, Germany).

The resultant raw sequence data were then processed using the Staden software package (1986, Nucleic Acids Research,

- 5 14:217-231), version 97-0. The individual sequences of the pZero1 derivatives were assembled into a cohesive contig. Computer-aided coding range analysis was performed using XNIP software (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analysis was performed using the
- "BLAST search programs" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402), against the non-redundant database of the "National Center for Biotechnology Information" (NCBI, Bethesda, MD, USA).

The resultant nucleotide sequence of the dapC gene is stated in SEQ ID no. 1. Analysis of the nucleotide sequence revealed an open reading frame of 1101 base pairs, which was designated the dapC gene. The dapC gene encodes a polypeptide of 367 amino acids, which is shown in SEQ ID no. 2.

#### 20 Example 3

Production of a shuttle vector pXT-dapCexp for enhancing the dapC gene in C. glutamicum

3.1. Cloning of the dapC gene

Chromosomal DNA was isolated from strain ATCC 13032 using the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)). On the basis of the sequence of the dapC gene for C. glutamicum known from Example 2, the following oligonucleotides were selected for the polymerase chain reaction (c.f. also SEQ ID no. 5 and 6):

30 DapC (dCex1):

5 GAT CTA (GAA TTC) GCC TCA GGC ATA ATC TAA CG 3 DapC (dCexna2):

5 GAT CTA (TCT AGA) CAG AGG ACA AGG CAA TCG GA 3

The stated primers were synthesized by the company ARK Scientific GmbH Biosystems (Darmstadt, Germany) and the PCR reaction performed in accordance with the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) using Pwo polymerase from Roche Diagnostics GmbH (Mannheim, Germany). By means of the polymerase chain reaction, the primers permit the amplification of an approx. 1.6 kb DNA fragment, which bears the dapC gene. Moreover, the primer DapC (dCex1) contains the sequence for the restriction site of the restriction endonuclease EcoRI, and the primer DapC (dCexna2) contains the restriction site of the restriction endonuclease XbaI, which are indicated between brackets in

The amplified approx. 1.6 kb DNA fragment, which bears the dapC gene, was ligated into the vector pCR®Blunt II (Bernard et al., Journal of Molecular Biology, 234:534-541 (1993)) using the Zero Blunt™ Kit from Invitrogen Corporation (Carlsbad, CA, USA; catalogue number K2700-20).

the above-stated nucleotide sequence.

- The E. coli strain Top10 was then transformed with the ligation batch in accordance with the kit manufacturer's instructions (Invitrogen Corporation, Carlsbad, CA, USA). Plasmid-bearing cells were selected by plating the transformation batch out onto LB agar (Sambrook et al.,
- 25 Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) which had been supplemented with 25 mg/l of kanamycin. Plasmid DNA was isolated from a transformant using the QIAprep Spin Miniprep Kit from Qiagen (Hilden,
- 30 Germany) and verified by restriction with the restriction enzymes XbaI and EcoRI and subsequent (0.8%) agarose gel electrophoresis. The DNA sequence of the amplified DNA fragment was verified by sequencing. The plasmid was named pCRdapC. The strain was designated E. coli Top10 / pCRdapC.
- 35 3.2. Production of the E. coli-C. glutamicum shuttle vector pEC-XT99A

The E. coli expression vector pTRC99A (Amann et al. 1988, Gene 69:301-315) was used as the starting vector for constructing the E. coli-C. glutamicum shuttle expression vector pEC-XT99A. After BspHI restriction cleavage (Roche

- Diagnostics GmbH, Mannheim, Germany, production description BspHI, product no. 1467123) and subsequent Klenow treatment (Amersham Pharmacia Biotech, Freiburg, Germany, product description Klenow Fragment of DNA Polymerase I, product no. 27-0928-01; method according to Sambrook et al., 1989,
- 10 Molecular Cloning: A Laboratory Manual, Cold Spring
  Harbor), the ampicillin resistance gene (bla) was replaced
  by the tetracycline resistance gene of C. glutamicum
  plasmid pAG1 (GenBank accession no. AF121000). To this end,
  the region bearing the resistance gene was cloned as an
- 15 AluI fragment (Amersham Pharmacia Biotech, Freiburg, Germany, product description AluI, product no. 27-0884-01) into the linearized E. coli expression vector pTRC99A. Ligation was performed as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring
- 20 Harbor), the DNA mixture being incubated overnight with T4 ligase (Amersham Pharmacia Biotech, Freiburg, Germany, product description T4 DNA Ligase, product no. 27-0870-04). This ligation mixture was then electroporated into the E. coli strain DH5αmcr (Grant, 1990, Proceedings of the
- 25 National Academy of Sciences U.S.A., 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7). The constructed E. coli expression vector was designated pXT99A.
- Plasmid pGA1 (Sonnen et al. 1991, Gene, 107:69-74) was used as the basis for cloning a minimal replicon from Corynebacterium glutamicum. By means of BalI/PstI restriction cleavage (Promega GmbH, Mannheim, Germany, production description BalI, product no. R6691; Amersham Pharmacia Biotech, Freiburg, Germany, production
- description PstI, product no. 27-0976-01) of the pGA1 vector, it proved possible to clone a 3484 bp fragment into the pK18mob2 vector (Tauch et al., 1998, Archives of Microbiology 169:303-312) which had been fragmented with

SmaI und PstI (Amersham Pharmacia Biotech, Freiburg, Germany, product description SmaI, product no. 27-0942-02, product description PstI, product no. 27-0976-01). An 839 bp fragment was deleted by BamHI/XhoI restriction cleavage

- 5 (Amersham Pharmacia Biotech, Freiburg, Germany, product description BamHI, product no. 27-086803, product description XhoI, product no. 27-0950-01) and subsequent Klenow treatment (Amersham Pharmacia Biotech, Freiburg, Germany, product description Klenow Fragment of DNA
- 10 Polymerase I, product no. 27-0928-01; method according to Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor). The C. glutamicum minimal replicon could be cloned into the E. coli expression vector pXT99A as a 2645 bp fragment from the construct which had
- 15 been religated with T4 ligase (Amersham Pharmacia Biotech, Freiburg, Germany, product description T4 DNA Ligase, product no. 27-0870-04). To this end, the DNA of the construct bearing the minimal replicon was cleaved with the restriction enzymes KpnI (Amersham Pharmacia Biotech,
- Freiburg, Germany, product description KpnI, product no. 27-0908-01) and PstI (Amersham Pharmacia Biotech, Freiburg, Germany, product description PstI, product no. 27-0886-03) and then a 3'-5'-exonuclease treatment (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring
- 25 Harbor) was performed by means of Klenow polymerase (Amersham Pharmacia Biotech, Freiburg, Germany, product description Klenow Fragment of DNA Polymerase I, product no. 27-0928-01).
- In a parallel batch, the E. coli expression vector pXT99A
  30 was cleaved with the restriction enzyme RsrII (Roche
  Diagnostics, Mannheim, Germany, product description RsrII,
  product no. 1292587) and prepared for ligation with Klenow
  polymerase (Amersham Pharmacia Biotech, Freiburg, Germany,
  Klenow Fragment of DNA Polymerase I, product no. 27-0928-
- 35 01). Ligation of the minimal replicon with the vector construct pXT99A was performed as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight

with T4 ligase (Amersham Pharmacia Biotech, Freiburg, Germany, product description T4 DNA Ligase, product no. 27-0870-40).

The E. coli-C. glutamicum shuttle expression vector pEC-5 XT99A constructed in this manner was transferred into C. glutamicum DSM5715 by electroporation (Liebl et al., 1989, FEMS Microbiology Letters, 53:299-303). Transformant selection proceeded on LBHIS agar consisting of 18.5 g/l of brain-heart infusion bouillon, 0.5 M sorbitol, 5 g/l of 10 Bacto tryptone, 2.5 g/l of Bacto yeast extract, 5 g/l of NaCl and 18 g/l of Bacto agar, which had been supplemented with 5 mg/l of tetracycline. Incubation was performed for 2 days at 33°C.

Plasmid DNA was isolated from a transformant using the
conventional methods (Peters-Wendisch et al., 1998,
Microbiology, 144, 915 - 927), cut with the restriction
endonuclease HindIII and the plasmid verified by subsequent
agarose gel electrophoresis.

The resultant plasmid construct was named pEC-XT99A and is shown in Figure 1. The strain obtained by electroporation of plasmid pEC-XT99A into Corynebacterium glutamicum DSM5715 was named DSM5715/pEC-XT99A and has been deposited with Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

3.3. Cloning of dapC in the E. coli-C. glutamicum shuttle vector pEC-XT99A

The vector used was the E. coli-C. glutamicum shuttle vector pEC-XT99A described in Example 3.2. DNA from this plasmid was completely cleaved with the restriction enzymes EcoRI and XbaI and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, product no. 1758250).

The dapC gene was isolated from the plasmid pCRdapC described in Example 3.1. by complete cleavage with the enzymes EcoRI and XbaI. The approx. 1600 bp dapC fragment was isolated from the agarose gel using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany).

The dapC fragment obtained in this manner was mixed with the prepared pEC-XT99A vector and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, 10 product description T4 DNA Ligase, code no. 27-0870-04). The ligation batch was then transformed into E. coli strain DH5 $\alpha$  (Hanahan, in: DNA Cloning, A Practical Approach, Vol. I, IRL-Press, Oxford, Washington DC, USA). Plasmid-bearing cells were selected by plating the transformation batch out 15 onto LB agar (Lennox, 1955, Virology, 1:190) with 5 mg/l of tetracycline. After overnight incubation at 37°C, individual recombinant clones were selected. Plasmid DNA was isolated from a transformant in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep 20 Kit (product no. 27106, Qiagen, Hilden, Germany) and cleaved with the restriction enzymes EcoRI and XbaI in order to verify the plasmid by subsequent agarose gel electrophoresis. The resultant plasmid was named pXTdapCexp. It is shown in Figure 2.

#### 25 Example 4

Transformation of strain DSM5715 with plasmid pXT-dapCexp

Strain DSM5715 was then transformed with plasmid pXT-dapCexp using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)).

- 30 Transformant selection proceeded on LBHIS agar consisting of 18.5 g/l of brain-heart infusion bouillon, 0.5 M sorbitol, 5 g/l of Bacto tryptone, 2.5 g/l of Bacto yeast extract, 5 g/l of NaCl and 18 g/l of Bacto agar, which had been supplemented with 5 mg/l of tetracycline. Incubation
- 35 was performed for 2 days at 33°C.

Plasmid DNA was isolated from a transformant using the conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cut with the restriction endonucleases EcoRI and XbaI and the plasmid was verified by subsequent agarose gel electrophoresis. The resultant strain was named DSM5715/pXT-dapCexp and has been deposited as DSM 13254 with Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

#### Example 5

Production of L-lysine

The C. glutamicum strain DSM5715/pXT-dapCexp obtained in Example 4 was cultured in a nutrient medium suitable for the production of lysine and the lysine content of the culture supernatant was determined.

To this end, the strain was initially incubated for 24 hours at 33°C on an agar plate with the appropriate antibiotic (brain/heart agar with tetracycline (5 mg/l)).

10 Starting from this agar plate culture, a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask). The complete medium CgIII was used as the medium for this preculture.

#### Medium Cg III

NaCl	2.5 g/l
Bacto peptone	10 g/l
Bacto yeast extract	10 g/l
Glucose (separately autoclaved)	2% (w/v)

The pH value was adjusted to pH 7.4.

15

Tetracycline (5 mg/l) was added to this medium. The preculture was incubated for 16 hours at 33°C on a shaker at 240 rpm. A main culture was inoculated from this preculture, such that the initial OD (660 nm) of the main culture was 0.1. Medium MM was used for the main culture.

#### Medium MM

CSL (Corn Steep Liquor)	5 g/l
MOPS (morpholinopropanesulfonic acid)	20 g/l
Glucose (separately autoclaved)	50 g/l
$(NH_4)_2SO_4$	25 g/l
KH <sub>2</sub> PO <sub>4</sub>	0.1 g/l
MgSO <sub>4</sub> * 7 H <sub>2</sub> O	1.0 g/l
CaCl <sub>2</sub> * 2 H <sub>2</sub> O	10 mg/l
FeSO <sub>4</sub> * 7 H <sub>2</sub> O	10 mg/l
MnSO <sub>4</sub> * H <sub>2</sub> O	5.0mg/l
Biotin (sterile-filtered)	0.3 mg/l
Thiamine * HCl (sterile-filtered)	0.2 mg/l
L-leucine (sterile-filtered)	0.1 g/l
CaCO <sub>3</sub>	25 g/l

CSL, MOPS and the salt solution were adjusted to pH 7 with ammonia water and autoclaved. The sterile substrate and vitamin solutions, together with the dry-autoclaved CaCO<sub>3</sub> are then added.

Culturing is performed in a volume of 10 ml in a 100 ml Erlenmeyer flask with flow spoilers. Tetracycline (5 mg/l) was added. Culturing was performed at 33°C and 80% atmospheric humidity.

After 72 hours, the OD was determined at a measurement wavelength of 660 nm using a Biomek 1000 (Beckmann Instruments GmbH, Munich). The quantity of lysine formed

was determined using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.

Table 1 shows the result of the test.

Table 1

Strain	OD (660 nm)	Lysine HCl 25 g/l
DSM5715	7.0	13.7
DSM5715/pXT-dapCexp	7.1	14.7

#### SEQUENCE LISTING

<110>	Degussa-Huels	AG
\ <u>_</u>	Degassa maers	110

5 <120> Nucleotide Sequences Coding for the dapC Gene and Process for the Production of L-Lysine.

<130> 990217 BT

10 <140> <141>

<160> 6

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 1300

<212> DNA

20 <213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (91)..(1191)

25 <223> dapC-Gene

<400> 1

gggctcccca ggtggtgcgg ctaagcttgg accacaagat tttgatcacc caatgatcgc 60

30 tgcgctgccg cctcaggcat aatctaacgc atg acc tct cgc acc ccg ctt gtt 114

Met Thr Ser Arg Thr Pro Leu Val

1 5

tot gtt ott oot gat ttt oog tgg gat tog oto got too goa aaa goo 162 35 Ser Val Leu Pro Asp Phe Pro Trp Asp Ser Leu Ala Ser Ala Lys Ala 10 15 20

aaa gct gcg tct cac ccg gat ggg atc gtg aat ctt tct gtt ggc act
Lys Ala Ala Ser His Pro Asp Gly Ile Val Asn Leu Ser Val Gly Thr
40 25 30 35 40

ccg gtt gat ccg gtc gcg ccc agc att cag atc gcg ttg gca gaa gca 258
Pro Val Asp Pro Val Ala Pro Ser Ile Gln Ile Ala Leu Ala Glu Ala
45 50 55

gcg ggg ttt tcg ggt tac cct caa acc atc ggc acc ccg gaa ctc cgc
Ala Gly Phe Ser Gly Tyr Pro Gln Thr Ile Gly Thr Pro Glu Leu Arg
60 65 70

50 gca gcc atc agg ggc gcg ctt gag cgg cgc tac aac atg aca aag ctt 354 Ala Ala Ile Arg Gly Ala Leu Glu Arg Arg Tyr Asn Met Thr Lys Leu 75 80 85

gtc gac gcc tcc ctc ctc ccc gtc gtg ggt acc aag gag gca att gcc 402 55 Val Asp Ala Ser Leu Leu Pro Val Val Gly Thr Lys Glu Ala Ile Ala 90 95 100

ctt ctt cca ttc gcg ttg ggt att tcc ggc acc gtt gtc atc cca gag 450 Leu Leu Pro Phe Ala Leu Gly Ile Ser Gly Thr Val Val Ile Pro Glu 60 105 110 115 120

	att Ile	gcg Ala	tac Tyr	cca Pro	acc Thr 125	tac Tyr	gaa Glu	gtc Val	gct Ala	gtc Val 130	gtg Val	gcc Ala	gca Ala	gga Gly	tgc Cys 135	acc Thr	498
5	gtg Val	ttg Leu	cgt Arg	tct Ser 140	gat Asp	tcg Ser	ctg Leu	ttt Phe	aag Lys 145	ctc Leu	ggc Gly	ccg Pro	cag Gln	atc Ile 150	ccg Pro	tcg Ser	546
10	atg Met	atg Met	ttt Phe 155	atc Ile	aac Asn	tca Ser	cca Pro	tcc Ser 160	aac Asn	ccc Pro	aca Thr	ggc Gly	aag Lys 165	gtt Val	ctg Leu	ggc Gly	594
15	atc Ile	cca Pro 170	cac His	ttg Leu	cgc Arg	aag Lys	gtt Val 175	gtg Val	aag Lys	tgg Trp	gcg Ala	cag Gln 180	gaa Glu	aac Asn	aac Asn	gtg Val	642
20	atc Ile 185	ctc Leu	gca Ala	gct Ala	gat Asp	gaa Glu 190	tgc Cys	tac Tyr	ttg Leu	ggt Gly	ctt Leu 195	ggc Gly	tgg Trp	gac Asp	gat Asp	gaa Glu 200	690
20	aac Asn	cca Pro	ccg Pro	atc Ile	tca Ser 205	att Ile	ttg Leu	gat Asp	cca Pro	cgt Arg 210	gtc Val	tgc Cys	gat Asp	ggc Gly	gac Asp 215	cac His	738
25	acc Thr	aac Asn	ttg Leu	atc Ile 220	gcc Ala	att Ile	cac His	tcg Ser	ctg Leu 225	tct Ser	aaa Lys	acc Thr	tca Ser	aac Asn 230	ctc Leu	gct Ala	786
30	tct Ser	tac Tyr	cgc Arg 235	gca Ala	ggt Gly	tac Tyr	ctc Leu	gtt Val 240	ggc	gat Asp	cca Pro	gcg Ala	ctg Leu 245	att Ile	ggt Gly	gaa Glu	834
35	ctc Leu	acg Thr 250	Glu	gtc Val	cgt Arg	aag Lys	aac Asn 255	ttg Leu	ggt Gly	ctc Leu	atg Met	gtt Val 260	Pro	ttc Phe	cca Pro	atc Ile	882
4.0	cag Gln 265	cag Gln	gcc Ala	atg Met	atc Ile	gca Ala 270	gcc Ala	ctc Leu	aac Asn	gac Asp	gat Asp 275	Asp	caa Gln	gag Glu	gca Ala	999 380 280	930
40	cag Gln	aag Lys	ctc Leu	acc Thr	tac Tyr 285	Ala	att Ile	cgt Arg	. cga Arg	gca Ala 290	. Lys	cto Lev	atg Met	cgc Arg	gcc Ala 295	ctg Leu	978
45	ttg Leu	gaa Glu	tcc Ser	ggc Gly 300	Phe	cag Gln	gta Val	gat Asp	aat Asr 305	ı Ser	gaa Glu	a gcg a Ala	ggt Gly	ctg Leu 310	Tyr	ctc Leu	1026
50	tgg Trp	gcg Ala	acg Thr	Arg	gaa Glu	gaa Glu	. cct Pro	tgc Cys 320	: Arg	gad g As <u>r</u>	act Thi	gto Val	gat Asp 325	Trp	tto Phe	gct Ala	1074
55	gag Glu	cgt Arg 330	g Gly	att Ile	cto Leu	gtt Val	gcc Ala 335	Pro	a gga	a gad y Asl	c tto p Pho	c tat e Ty: 340	c GTZ	c cct / Pro	cgo Arg	e gga g Gly	1122
60	gce Ala 345	ı Glr	g cat n His	gtg Val	g cgt L Arg	gtg Val	. Ala	ato Met	g aco	c gaa r Gli	a accurate	r Asl	gag Gli	g cgo ı Arg	g gto g Val	gac l Asp 360	1170
60	gco Ala	tti a Phe	t gtt e Val	tct L Sei	c cgc c Arc 369	g Lei	g ago 1 Sei	taa C	aaca	cgac	taa	gctt	att 1	ttgtt	taa	tt	1221
65	gag	gttt	gaag	ttti	tccgt	tog a	aaaga	aggc	ca t	ttga	gttc	c ga	gtcc	agtc	ctg	agtcga	g 1281

#### taccgagcaa aaaacctgg

5	<21:	0 > 2 1 > 3 2 > P 3 > C		ebact	teri	ım gi	Lutar	nicur	n							
10		0> 2 Thr	Ser	Arg	Thr 5	Pro	Leu	Val	Ser	Val 10	Leu	Pro	Asp	Phe	Pro 15	Trp
15	Asp	Ser	Leu	Ala 20	Ser	Ala	Lys	Ala	Lys 25	Ala	Ala	Ser	His	Pro 30	Asp	Gly
13	Ile	Val	Asn 35	Leu	Ser	Val	Gly	Thr 40	Pro	Val	Asp	Pro	Val 45	Ala	Pro	Ser
20	Ile	Gln 50	Ile	Ala	Leu	Ala	Glu 55	Ala	Ala	Gly	Phe	Ser 60	Gly	Tyr	Pro	Gln
	Thr 65	Ile	Gly	Thr	Pro	Glu 70	Leu	Arg	Ala	Ala	Ile 75	Arg	Gly	Ala	Leu	Glu 80
25	Arg	Arg	Tyr	Asn	Met 85	Thr	Lys	Leu	Val	Asp 90	Ala	Ser	Leu	Leu	Pro 95	Val
30	Val	Gly	Thr	Lys 100	Glu	Ala	Ile	Ala	Leu 105	Leu	Pro	Phe	Ala	Leu 110	Gly	Ile
30	Ser	Gly	Thr 115	Val	Val	Ile	Pro	Glu 120	Ile	Ala	Tyr	Pro	Thr 125	Tyr	Glu	Val
35	Ala	Val 130	Val	Ala	Ala	Gly	Cys 135	Thr	Val	Leu	Arg	Ser 140	Asp	Ser	Leu	Phe
	Lys 145	Leu	Gly	Pro	Gln	Ile 150	Pro	Ser	Met	Met	Phe 155	Ile	Asn	Ser	Pro	Ser 160
40	Asn	Pro	Thr	Gly	Lys 165	Val	Leu	Gly	Ile	Pro 170	His	Leu	Arg	Lys	Val 175	Val
45	Lys	Trp	Ala	Gln 180	Glu	Asn	Asn	Val	Ile 185	Leu	Ala	Ala	Asp	Glu 190	Cys	Tyr
	Leu	Gly	Leu 195	Gly	Trp	Asp	Asp	Glu 200	Asn	Pro	Pro	Ile	Ser 205	Ile	Leu	Asp
50	Pro	Arg 210	Val	Cys	Asp	Gly	Asp 215	His	Thr	Asn	Leu	Ile 220	Ala	Ile	His	Ser
	Leu 225	Ser	Lys	Thr	Ser	Asn 230	Leu	Ala	Ser	Tyr	Arg 235	Ala	Gly	Tyr	Leu	Val 240
55	Gly	Asp	Pro	Ala	Leu 245	Ile	Gly	Glu	Leu	Thr 250	Glu	Val	Arg	Lys	Asn 255	Leu
60	Gly	Leu	Met	Val 260	Pro	Phe	Pro	Ile	Gln 265	Gln	Ala	Met	Ile	Ala 270	Ala	Leu
- •	Asn	Asp	Asp 275	Asp	Gln	Glu	Ala	Gly 280	Gln	Lys	Leu	Thr	Tyr 285	Ala	Ile	Arg
65	Arg	Ala 290	Lys	Leu	Met	Arg	Ala 295	Leu	Leu	Glu	Ser	Gly 300	Phe	Gln	Val	Asp

	Asn 305	Ser	Glu	Ala	Gly	Leu 310	Tyr	Leu	Trp	Ala	Thr 315	Arg	Glu	Glu	Pro	Cys 320	
5	Arg	Asp	Thr	Val	Asp 325	Trp	Phe	Ala	Glu	Arg 330	Gly	Ile	Leu	Val	Ala 335	Pro	
	Gly	Asp	Phe	Tyr 340	Gly	Pro	Arg	Gly	Ala 345	Gln	His	Val	Arg	Val 350	Ala	Met	
10	Thr	Glu	Thr 355	Asp	Glu	Arg	Val	Asp 360	Ala	Phe	Val	Ser	Arg 365	Leu	Ser		
15	<212	L> 13 2> Di	A	ebact	ceriu	ım g]	Lutar	nicur	n								
20	<222	)> L> CI 2> (9 3> da	91).	•													
25	<400 ggg		cca g	ggtgg	gtgcg	gg ct	caago	cttgg	g ac	cacaa	agat	ttt	gatca	acc (	caat	gatege	60
30	tgcg	gctgo	ccg (	cctca	aggca	at aa	atcta	aacgo	Met	-		_	g Thi		-	t gtt ı Val	114
35	tct Ser	gtt Val 10	ctt Leu	cct Pro	gat Asp	ttt Phe	ccg Pro 15	tgg Trp	gat Asp	tcg Ser	ctc Leu	gct Ala 20	tcc Ser	gca Ala	aaa Lys	gcc Ala	162
					cac His												210
40					gtc Val 45												258
45				_	ggt Gly											_	306
50					ggc Gly												354
55					ctc Leu												402

ctt ctt cca ttc gcg ttg ggt att tcc ggc acc gtt gtc atc cca gag Leu Leu Pro Phe Ala Leu Gly Ile Ser Gly Thr Val Val Ile Pro Glu

															tgc Cys 135		498
5															ccg Pro		546
10															ctg Leu		594
15															aac Asn		642
20			_	_	_	_	-		_					-	gat Asp	_	690
															gac Asp 215		738
25															ctc Leu		786
30	tct Ser														ggt Gly		834
35															cca Pro		882
40															gca Ala		930
	_	_				~ ~		_	_	_			_	_	gcc Ala 295	_	978
45															tac Tyr		1026
50															ttc Phe		1074
55															cgc Arg		1122
60	gcg Ala 345	cag Gln	cat His	gtg Val	cgt Arg	gtg Val 350	gcg Ala	atg Met	acc Thr	gaa Glu	acc Thr 355	gac Asp	gag Glu	cgc Arg	gtc Val	gac Asp 360	1170
- 0						ctg Leu		taa	acac	gac '	taag	ctta <sup>.</sup>	tt t	tgtt:	taat	t	1221
65	gag	tttg	aag	tttt	ccgt	cg a	aaga	ggcc	a tt	tgag	ttcc	gag	tcca	gtc	ctga	gtcgag	1281

#### taccgagcaa aaaacctgg

5	<210> 4 <211> 367 <212> PRT <213> Corynebacterium glutamicum															
10		0> 4 Thr	Ser	Arg	Thr 5	Pro	Leu	Val	Ser	Val 10	Leu	Pro	Asp	Phe	Pro 15	Trp
15	Asp	Ser	Leu	Ala 20	Ser	Ala	Lys	Ala	Lys 25	Ala	Ala	Ser	His	Pro 30	Asp	Gly
0	Ile	Val	Asn 35	Leu	Ser	Val	Gly	Thr 40	Pro	Val	Asp	Pro	Val 45	Ala	Pro	Ser
20	Ile	Gln 50	Ile	Ala	Leu	Ala	Glu 55	Ala	Ala	Gly	Phe	Ser 60	Gly	Tyr	Pro	Gln
	Thr 65	Ile	Gly	Thr	Pro	Glu 70	Leu	Arg	Ala	Ala	Ile 75	Arg	Gly	Ala	Leu	Glu 80
25	Arg	Arg	Tyr	Asn	Met 85	Thr	Lys	Leu	Val	Asp 90	Ala	Ser	Leu	Leu	Pro 95	Val
30	Val	Gly	Thr	Lys 100	Glu	Ala	Ile	Ala	Leu 105	Leu	Pro	Phe	Ala	Leu 110	Gly	Ile
50	Ser	Gly	Thr 115	Val	Val	Ile	Pro	Glu 120	Ile	Ala	Tyr	Pro	Thr 125	Tyr	Glu	Val
35	Ala	Val 130	Val	Ala	Ala	Gly	Cys 135	Thr	Val	Leu	Arg	Ser 140	Asp	Ser	Leu	Phe
	Lys 145	Leu	Gly	Pro	Gln	Ile 150	Pro	Ser	Met	Met	Phe 155	Ile	Asn	Ser	Pro	Ser 160
40	Asn	Pro	Thr	Gly	Lys 165	Val	Leu	Gly	Ile	Pro 170	His	Leu	Arg	Lys	Val 175	Val
45	Lys	Trp	Ala	Gln 180	Glu	Asn	Asn	Val	Ile 185	Leu	Ala	Ala	Asp	Glu 190	Cys	Tyr
	Leu	Gly	Leu 195	Gly	Trp	Asp	Asp	Glu 200	Asn	Pro	Pro	Ile	Ser 205	Ile	Leu	Asp
50	Leu	Arg 210	Val	Cys	Asp	Gly	Asp 215	His	Thr	Asn	Leu	Ile 220	Ala	Ile	His	Ser
	Leu 225	Ser	Lys	Thr	Ser	Asn 230	Leu	Ala	Ser	Tyr	Arg 235	Ala	Gly	Tyr	Leu	Val 240
55	Gly	Asp	Pro	Ala	Leu 245	Ile	Gly	Glu	Leu	Thr 250	Glu	Val	Arg	Lys	Asn 255	Leu
60	Gly	Leu	Met	Val 260	Pro	Phe	Pro	Ile	Gln 265	Gln	Ala	Met	Ile	Ala 270	Ala	Leu
- •	Asn	Asp	Asp 275	Asp	Gln	Glu	Ala	Gly 280	Gln	Lys	Leu	Thr	Tyr 285	Ala	Ile	Arg
65	Arg	Ala 290	Lys	Leu	Met	Arg	Ala 295	Leu	Leu	Glu	Ser	Gly 300	Phe	Gln	Val	Asp

	Asn Ser Glu Ala Gly Leu Tyr Leu Trp Ala Thr Arg Glu Glu Pro Cys 305 310 315 320												
5	Arg Asp Thr Val Asp Trp Phe Ala Glu Arg Gly Ile Leu Val Ala Pro 325 330 335												
	Gly Asp Phe Tyr Gly Pro Arg Gly Ala Gln His Val Arg Val Ala Met 340 345 350												
10	Thr Glu Thr Asp Glu Arg Val Asp Ala Phe Val Ser Arg Leu Ser 355 360 365												
15	<210> 5 <211> 32 <212> DNA <213> Artificial Sequence												
20	<220> <223> Description of Artificial Sequence: Primer												
25	<220> <223> Primer DapC (dCex1)  <400> 5 gatctagaat tcgcctcagg cataatctaa cg												
30	<210> 6 <211> 32 <212> DNA <213> Artificial Sequence												
35	<220> <223> Description of Artificial Sequence: Primer												
40	<220> <223> Primer DapC (dCexna2)												
	<400> 6 gatctatcta gacagaggac aaggcaatcg ga	32											